Replies to post #143573 on Biotech Values

[DewDiligence]

…I can think of only two cases where I am pretty sure I know what went wrong - in one instance they enrolled Eastern European patients in a semi-secretive fashion, and in another they clearly didn't target the right subgroup and when they did the post hoc analysis it was clear as day and they then went back and reran the ph iii successfully.

Which two companies are you referring to?